MUC1 Dendritic Cell Vaccine(Prima BioMed)

The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease progression.

The purpose of this study is to determine the safety and efficacy of an investigational therapeutic agent (Cvac) in ovarian cancer patients in first or second remission and to determine its ability to prevent cancer from returning.
Study objectives
Primary objectives:
To confirm the safety of administering Cvac in this population.
To determine the effects of Cvac on progression-free survival (PFS).
Secondary objectives:
To determine overall survival (OS) for ovarian cancer patients who receive Cvac after achieving remission in the first or second-line setting.
Evaluation of host immunologic response to Cvac administration.